Organophosphorus (OP) compounds inhibit acetylcholinesterase (AChE) by forming a covalent phosphoryl-enzyme adduct at the catalytic serine-200 residue of the esteratic site. Unlike the carbamylation produced by neostigmine or pyridostigmine, this phosphorylation is initially reversible by oxime reactivators but undergoes a time-dependent dealkylation reaction called aging, after which the adduct becomes permanently irreversible. The kinetics of aging define the treatment window for pralidoxime (2-PAM) and are the critical pharmacological variable distinguishing therapeutic success from futility in OP poisoning.
Mechanism of Phosphorylation. The phosphorus atom of an organophosphate compound acts as an electrophilic center that attacks the nucleophilic hydroxyl group of serine-200 in the AChE active site, forming a tetrahedral transition state that resolves by displacement of the leaving group (the non-phosphorus substituent of the OP). The resulting phosphoryl-enzyme bond is a phosphoester linkage that is hydrolyzed by water approximately one million times more slowly than the normal acetyl-enzyme intermediate, producing what is operationally described as irreversible inhibition. The non-phosphorylated serine of the regenerated enzyme never accumulates because the phosphorylated form is kinetically trapped: spontaneous reactivation under physiological conditions occurs at a rate of hours to days rather than milliseconds. The consequence is persistent, accumulating inhibition of AChE at all cholinergic synapses, with acetylcholine (ACh) building up in the synaptic cleft and producing continuous, uncontrolled activation of both muscarinic and nicotinic receptors.1
Nerve Agents vs. Pesticide OPs. Organophosphate compounds span two clinically important categories: chemical warfare nerve agents and agricultural or household pesticide OPs. Nerve agents include the G-series (tabun [GA], sarin [GB], soman [GD], and cyclosarin [GF]) and the V-series (VX, VR), both groups sharing extreme potency and rapid onset of action but differing in volatility, skin penetration, and aging rates. G-series agents are volatile and primarily absorbed by inhalation; V-series agents such as VX are dense oily liquids with low volatility but exceptional percutaneous absorption, making skin contact the dominant exposure route. Pesticide OPs include parathion, malathion, chlorpyrifos, diazinon, and dichlorvos. Parathion and chlorpyrifos are among the most potent and are associated with the majority of severe agricultural OP poisoning fatalities worldwide.2 Malathion has substantially lower mammalian toxicity than parathion because it requires bioactivation to malaoxon but is efficiently detoxified by carboxylesterases present in mammals but absent in insects, providing a degree of selective toxicity.4
The Aging Phenomenon. After the initial phosphorylation of AChE, the phosphoryl-enzyme adduct undergoes a spontaneous dealkylation reaction in which one of the alkyl groups attached to the phosphorus is eliminated, converting the dialkyl-phosphorylated enzyme into a monoalkyl or dealkylated form that is resistant to nucleophilic attack by oximes. This process is called aging. Aging rates vary enormously across OP compounds and determine the practical window for oxime therapy. Soman (GD) ages within minutes (half-life 2 to 6 minutes), which is why standard 2-PAM therapy is essentially futile against soman poisoning unless administered within the first few minutes of exposure. Sarin ages with a half-life of approximately 3 to 5 hours, VX ages over 36 to 48 hours, and common pesticide OPs such as parathion and chlorpyrifos age over 12 to 36 hours. The clinical implication is that 2-PAM has a meaningful treatment window for most pesticide OP poisonings and for VX exposure, but its efficacy is severely limited in soman poisoning. For practical purposes, 2-PAM should be administered as early as possible in all OP poisonings and continued for at least 24 to 48 hours in pesticide cases, even if the initial dose appears clinically insufficient.1311
Soman (GD): 2 to 6 minutes — 2-PAM essentially futile after first few minutes; pretreatment with pyridostigmine is the primary prophylactic strategy. Sarin (GB): 3 to 5 hours — 2-PAM effective if given early. VX: 36 to 48 hours — 2-PAM effective with early and sustained dosing. Parathion/chlorpyrifos: 12 to 36 hours — 2-PAM window is wide; initiate immediately and continue. Tabun (GA): ages in approximately 13 to 14 hours but 2-PAM is poorly effective against tabun adducts regardless of timing due to the structure of the adduct; obidoxime is preferred for tabun in military settings.
The clinical severity of OP (organophosphate) poisoning is shaped as much by pharmacokinetic variables as by the intrinsic potency of the compound. Organophosphates as a class are highly lipid-soluble molecules that readily penetrate all biological membranes, including the skin, mucous membranes, cornea, gastrointestinal (GI) epithelium, lung alveoli, and the blood-brain barrier (BBB). This broad absorption capability means that no route of exposure can be considered trivial, and decontamination must address all potential routes simultaneously.
Absorption Routes and Lipid Solubility. Inhalation is the fastest and most dangerous route of OP exposure for volatile agents: nerve agent vapor can produce incapacitating effects within seconds to minutes of inhalation because absorption across the alveolar-capillary membrane is nearly instantaneous and systemic distribution is immediate. Dermal absorption is the dominant route for non-volatile agents such as VX (a V-series nerve agent) and for agricultural OP pesticides encountered during spraying operations; the rate of dermal penetration depends on the lipid-water partition coefficient of the specific compound, the integrity of the skin, and whether protective clothing was worn. Oral ingestion is the most common route in intentional self-poisoning with agricultural OPs, which accounts for a large proportion of poisoning fatalities in South and Southeast Asia. Conjunctival absorption is clinically relevant for aerosol exposures and is responsible for the early miosis (pupillary constriction) that can serve as a diagnostic sign even before systemic symptoms appear. All organophosphates are highly protein-bound in plasma and distribute widely into fat and muscle depots, creating a large volume of distribution that means serum concentrations do not reflect total body burden, and prolonged or biphasic clinical courses can result from redistribution from tissue stores hours after initial apparent stabilization.4
Bioactivation of Thiono-OPs. A pharmacokinetically important subclass of organophosphate pesticides are the thiono-OPs, in which the P=O (phosphoryl) bond of the active inhibitor is replaced by a P=S (phosphorothioyl or thiono) bond. Thiono-OPs include parathion, malathion, chlorpyrifos, and diazinon. In their thiono form, these compounds are weak AChE inhibitors because the sulfur reduces the electrophilicity of the phosphorus atom and therefore its capacity to phosphorylate the serine hydroxyl. Bioactivation to the corresponding oxon (P=O) form by cytochrome P450 (CYP) oxidation in the liver and lung converts the thiono-OP into a potent AChE inhibitor: parathion becomes paraoxon, malathion becomes malaoxon, and chlorpyrifos becomes chlorpyrifos-oxon. This obligate hepatic bioactivation step has two important clinical consequences: onset of toxicity after oral ingestion of thiono-OPs may be delayed by 1 to 4 hours compared to direct-acting OPs such as nerve agents, and the rate of bioactivation is subject to interindividual variation and drug interactions involving CYP inducers or inhibitors that can modify both the severity and timing of toxicity.4
Central Penetration and Toxicity. All clinically significant organophosphates readily cross the BBB because of their high lipid solubility. CNS (central nervous system) AChE inhibition produces a distinct component of the OP toxidrome that is not adequately treated by peripheral muscarinic blockade with atropine alone. Central cholinergic hyperstimulation causes anxiety, restlessness, emotional lability, and cognitive impairment at moderate levels of AChE inhibition (50 to 70 percent inhibition of red blood cell (RBC) AChE), progressing to seizures, loss of consciousness, central respiratory depression, and coma at inhibition levels exceeding 70 to 80 percent. Seizures in OP poisoning are initially cholinergic in origin (driven by excessive ACh at muscarinic and nicotinic receptors in the limbic system and cortex) but rapidly evolve into self-sustaining status epilepticus (SE) driven by glutamatergic excitotoxicity and gamma-aminobutyric acid (GABA)-ergic failure independent of continued cholinergic drive. This transition from cholinergic to glutamatergic SE is the reason that benzodiazepines, which enhance GABA-A (gamma-aminobutyric acid type A) receptor function, remain effective as anticonvulsants in OP poisoning even after complete muscarinic receptor blockade has been achieved with atropine, and why delay in benzodiazepine administration worsens seizure control and outcome.35
The full cholinergic toxidrome produced by OP (organophosphate) poisoning results from the simultaneous accumulation of ACh at three anatomically distinct synaptic sites: postganglionic muscarinic synapses of the parasympathetic nervous system, nicotinic synapses at the neuromuscular junction (NMJ) and autonomic ganglia, and central nervous system (CNS) muscarinic and nicotinic receptors. Each component contributes distinct clinical features, and their severity correlates broadly with the degree of AChE inhibition measured in red blood cells (RBC/RBCs) or plasma.
Muscarinic Component. Muscarinic overstimulation of postganglionic parasympathetic effectors produces the features captured by two mnemonic frameworks. The Salivation, Lacrimation, Urination, Defecation, GI (gastrointestinal) cramping, Emesis (SLUDGE) mnemonic covers the cardinal features. The Diarrhea/Defecation, Urination, Miosis, Bradycardia/Bronchospasm/Bronchorrhea, Emesis, Lacrimation, Salivation (DUMBELS) mnemonic expands this to emphasize the cardiovascular and respiratory components. Both mnemonics identify the same spectrum of parasympathetic hyperactivity. Among these features, the triad of bronchospasm, bronchorrhea (copious airway secretions), and bradycardia represents the immediate life-threatening component of the muscarinic syndrome. Bronchospasm and bronchorrhea together produce hypoxia through airway obstruction and impaired gas exchange; bradycardia may progress to atrioventricular (AV) block and asystole in severe poisoning. Miosis is a near-universal early sign, often appearing before systemic symptoms in vapor exposure, but is not in itself life-threatening. Urinary and fecal incontinence reflect loss of sphincter control and are useful diagnostic markers but are not directly dangerous. Profuse diaphoresis (sweating) from eccrine sweat gland stimulation and increased salivation and lacrimation are consistent findings across all grades of severity.5
Nicotinic Component at the NMJ. Excessive ACh at the NMJ initially produces fasciculations (visible muscle twitching), a result of repetitive firing of motor endplate potentials. As AChE inhibition deepens, sustained depolarization of the endplate produces depolarizing neuromuscular blockade, manifesting clinically as profound flaccid weakness and respiratory muscle paralysis. The progression from fasciculations to weakness follows a predictable sequence: fine fasciculations first appear in the periorbital and facial muscles, then spread to the limbs and trunk. Diaphragmatic and intercostal muscle paralysis is the proximate cause of respiratory failure in severe OP poisoning. This respiratory failure is compounded by the concurrent muscarinic bronchospasm and bronchorrhea, by CNS respiratory center depression, and by the excess secretions aspiration risk from loss of airway protective reflexes. The combination of these four mechanisms of respiratory failure (NMJ paralysis, bronchospasm, bronchorrhea, and central apnea) makes early airway management the highest priority intervention in severe OP toxicity.15
Nicotinic Component at Autonomic Ganglia. ACh accumulation at nicotinic receptors in sympathetic and parasympathetic ganglia produces a ganglionic stimulation effect that partially opposes and partially compounds the postganglionic muscarinic effects. Ganglionic nicotinic stimulation activates both sympathetic and parasympathetic postganglionic neurons simultaneously, but because sympathetic postganglionic nerves release norepinephrine and because the adrenal medulla releases epinephrine (through its own nicotinic chromaffin cell receptors), early or mild OP poisoning may present with tachycardia and hypertension from sympathoadrenal activation rather than the expected bradycardia and hypotension. As poisoning progresses and parasympathetic postganglionic muscarinic effects predominate, the cardiovascular picture shifts to bradycardia, hypotension, and heart block. This biphasic cardiovascular pattern (initial sympathomimetic followed by parasympathomimetic predominance) can complicate the diagnosis of moderate poisoning and explains why some patients initially present with tachycardia before transitioning to bradycardia.5
Severity Grading by AChE Inhibition. The severity of OP poisoning correlates with the degree of AChE inhibition in RBCs (red blood cells), which is the preferred biomarker because RBC AChE reflects neuronal AChE inhibition more accurately than plasma butyrylcholinesterase (BuChE). Mild poisoning corresponds to approximately 20 to 50 percent RBC AChE inhibition and presents with miosis, rhinorrhea, headache, diaphoresis, and mild GI symptoms without severe bronchospasm or neuromuscular compromise. Moderate poisoning (50 to 70 percent inhibition) produces the full muscarinic syndrome plus fasciculations, weakness, and anxiety. Severe poisoning (greater than 70 percent inhibition) produces flaccid paralysis, respiratory failure, seizures, loss of consciousness, and coma. Plasma BuChE levels fall earlier and more rapidly than RBC AChE because BuChE has higher affinity for most OPs, making it a sensitive but less specific marker; very low plasma BuChE with normal RBC AChE indicates exposure without severe systemic inhibition. Serial RBC AChE measurements guide both initial severity assessment and the adequacy of antidote therapy over the course of treatment.35
1. NMJ depolarizing blockade: flaccid paralysis of diaphragm and intercostal muscles. 2. Bronchospasm: M3-mediated airway smooth muscle contraction increasing airway resistance. 3. Bronchorrhea: M3-mediated gland hypersecretion flooding the airways. 4. Central respiratory depression: CNS AChE inhibition suppressing medullary respiratory centers. All four act simultaneously in severe poisoning. Intubation and positive-pressure ventilation are the only interventions that address all four simultaneously; atropine does not reverse NMJ blockade or CNS depression.
Effective management of OP (organophosphate) poisoning requires simultaneous deployment of three pharmacological interventions targeting distinct pathophysiological mechanisms: atropine for muscarinic receptor blockade, pralidoxime (2-PAM) for AChE reactivation before aging occurs, and benzodiazepines for seizure prevention and treatment. Understanding the correct endpoint for each agent is as important as the dosing, because undertreating with atropine and overtreating with atropine-guided endpoints (such as heart rate rather than secretions) both produce avoidable harm.
Atropine: Mechanism, Dosing, and Endpoint. Atropine is a competitive antagonist at all muscarinic receptor subtypes, blocking the effects of accumulated ACh at M1 (muscarinic subtype 1) through M5 (muscarinic subtype 5) receptors in the smooth muscle, secretory glands, cardiac tissue, and central nervous system (CNS). Because atropine does not enter the AChE active site or reverse phosphorylation, it does not address the nicotinic component of the toxidrome (neuromuscular junction [NMJ] paralysis, fasciculations, ganglionic effects) and does not reactivate the inhibited enzyme. Atropine doses required in severe OP poisoning vastly exceed the doses used in other clinical contexts. The standard adult initial dose is 2 to 4 mg IV, repeated every 5 to 10 minutes and doubled with each successive dose until the secretion endpoint is reached. Total atropine requirements in severe poisoning frequently exceed 20 to 100 mg over the first several hours of treatment; reports of patients receiving 500 mg or more over the course of treatment exist in the severe agricultural OP poisoning literature.
Atropine Titration Endpoint. The correct titration endpoint is drying of bronchial secretions (cessation of bronchorrhea), not heart rate normalization. Using heart rate as the titration endpoint consistently leads to undertreatment because the nicotinic component of the toxidrome (tachycardia from ganglionic stimulation) can maintain tachycardia even in the presence of inadequate muscarinic blockade. Atropine may be given intramuscularly (IM) when IV access is not immediately available; the DuoDote autoinjector contains 2.1 mg atropine + 600 mg 2-PAM for this purpose. The blood-brain barrier (BBB) is not an obstacle for atropine, which crosses freely as a tertiary amine, making it effective against both peripheral muscarinic and central CNS components of OP toxicity.67
Pralidoxime (2-PAM): Mechanism, Timing, and Dosing. Pralidoxime (2-pyridine aldoxime methochloride, 2-PAM) is an oxime nucleophile that reactivates phosphorylated AChE by attacking the phosphorus atom of the enzyme adduct, forming a 2-PAM-phosphonate complex that dissociates from the enzyme, regenerating the free active serine. This reaction is specific for the dialkyl-phosphorylated enzyme before aging; after aging dealkylates the adduct, the resulting species is resistant to oxime attack because the nucleophilic trajectory to the phosphorus is sterically blocked or the electronic structure of the adduct has changed. The clinical dose of 2-PAM in adults is 1 to 2 g IV over 15 to 30 minutes (loading dose), followed by an infusion of 200 to 500 mg per hour continued for at least 24 to 48 hours or until clinical improvement is sustained and atropine requirements fall. Bolus injection of 2-PAM faster than over 5 to 10 minutes should be avoided because it can precipitate tachycardia, hypertension, laryngospasm, and neuromuscular blockade from the quaternary nitrogen moiety itself. The 2-PAM molecule does not cross the BBB to a clinically meaningful extent because it is a permanently charged quaternary compound, and therefore it does not address the central nervous system component of OP toxicity; this explains why atropine (which does cross the BBB) remains essential even when 2-PAM is given promptly.3712
Benzodiazepines for OP-Induced Seizures. Seizures in OP poisoning must be treated urgently because delayed treatment allows progression from cholinergic-mediated seizures to self-sustaining glutamatergic status epilepticus (SE) that becomes refractory to anticonvulsant therapy. Diazepam is the preferred benzodiazepine in military and mass-casualty OP poisoning settings, and the DuoDote autoinjector series also contains a separate 10 mg diazepam autoinjector. Lorazepam or midazolam are acceptable alternatives in hospital settings. The mechanism of seizure suppression is enhancement of GABA-A (gamma-aminobutyric acid type A) receptor chloride conductance, which hyperpolarizes neurons and raises the seizure threshold. Benzodiazepines remain effective even after complete muscarinic blockade has been achieved because the self-sustaining phase of OP seizures is glutamatergically driven rather than cholinergically driven. Current guidelines recommend prophylactic benzodiazepine administration in all patients with moderate to severe OP poisoning, not just those with active seizures, because preventing the transition to SE is easier and safer than treating established SE. Phenytoin is ineffective against OP-induced SE and should not be used as first-line therapy; it may be considered as an adjunct for refractory cases.58
Titrate atropine to secretion drying, not to heart rate. The target is cessation of bronchorrhea and reduction of bronchospasm sufficient to allow adequate ventilation; pupil dilation and tachycardia are expected atropine effects and confirm adequate dosing but are not themselves the target. Starting dose: 2 to 4 mg IV; double every 5 to 10 minutes until secretions dry. Inadequate atropinization is indicated by persistent wet crackles, copious oral secretions, or persistent bronchospasm. Over-atropinization is indicated by extreme tachycardia (>150 bpm without competing cholinergic drive), absent bowel sounds, urinary retention, and hyperthermia in an already warm patient.
While organophosphate (OP) and carbamate insecticides both inhibit AChE and produce a cholinergic toxidrome, fundamental differences in their mechanism of inhibition, aging kinetics, and central nervous system (CNS) penetration produce important distinctions in clinical management. Nerve agent exposures introduce additional considerations around decontamination sequencing, autoinjector use in the field, and the role of pyridostigmine pretreatment as a pharmacological countermeasure.
Carbamates vs. OPs: Key Pharmacological Differences. Carbamate insecticides (carbofuran, aldicarb, methomyl, carbaryl) inhibit AChE by carbamylation of the catalytic serine, the same reaction produced by the therapeutic carbamate AChE inhibitors neostigmine and pyridostigmine. The critical practical distinction from OP (organophosphate) inhibition is that carbamate-inhibited AChE does not age: the carbamyl-enzyme adduct spontaneously hydrolyzes with a half-life of 30 to 120 minutes, meaning that AChE activity gradually recovers even without antidote administration. This aging-independent spontaneous reactivation has two important consequences. First, pralidoxime (2-PAM) is not indicated for carbamate poisoning; the enzyme will reactivate spontaneously, and some experimental evidence suggests that 2-PAM may paradoxically inhibit AChE in carbamate poisoning or produce hemodynamic instability, though the human clinical data on this interaction are not definitive. Second, the clinical course of carbamate poisoning is generally shorter and more self-limited than equivalent-severity OP poisoning, with symptoms typically resolving within 6 to 24 hours in the absence of massive ongoing exposure.10 Atropine remains the mainstay of treatment for the muscarinic component of carbamate toxicity and is given by the same titration-to-secretion-drying principle as in OP poisoning. CNS penetration of carbamate insecticides is generally lower than for OP compounds because most carbamate insecticides are less lipid-soluble, but highly toxic carbamates such as carbofuran and aldicarb can produce CNS features including seizures and coma.9
Nerve Agent Decontamination Priorities. Decontamination is a prerequisite for safe and effective medical treatment of nerve agent casualties and must not be delayed by other interventions except for immediately life-threatening airway compromise. The sequence is (1) remove the patient from the contaminated environment; (2) remove all clothing and personal effects, which eliminates approximately 80 percent of the contaminant burden; (3) irrigate the skin with copious water or a 0.5 percent hypochlorite solution (diluted bleach), avoiding the eyes; (4) irrigate the eyes with water or saline if conjunctival exposure occurred. Decontamination personnel must be in appropriate personal protective equipment (PPE) to avoid secondary contamination. For liquid nerve agent (VX) exposure, gentle blotting of the skin followed by water irrigation is preferred because vigorous rubbing may increase dermal penetration. Gastric decontamination is not indicated for vapor or aerosol nerve agent exposure and is rarely relevant for liquid nerve agent exposure. The priority of decontamination over treatment must be balanced against the pharmacokinetics of the agent: for a G-series vapor exposure (sarin, soman), the agent is volatile and transient, so decontamination is less critical than immediate antidote administration; for VX liquid exposure, ongoing dermal absorption makes decontamination a higher relative priority because antidote administration without decontamination treats an ongoing exposure.67
Autoinjectors and Field Treatment Protocols. Military and emergency preparedness protocols use nerve agent antidote autoinjectors to allow self-administration or buddy-administration in the field before hospital care is available. The Mark 1 autoinjector kit (US military, now superseded) contained separate 2 mg atropine and 600 mg 2-PAM autoinjectors. The DuoDote autoinjector (current US military and civilian stockpile) delivers 2.1 mg atropine sulfate and 600 mg pralidoxime chloride in a single injection to the anterolateral thigh. For mild symptoms (miosis, rhinorrhea, mild GI distress), one DuoDote injection is administered. For moderate symptoms (severe GI symptoms, generalized weakness, bronchospasm), two to three injections are administered in rapid succession with continuous monitoring. For severe symptoms (loss of consciousness, seizures, respiratory failure), three injections are given immediately while additional medical care is summoned. Atropine autoinjectors (0.4 to 2 mg each) are available for supplemental dosing. Diazepam autoinjectors (10 mg) are used for seizure control. Pediatric dosing uses weight-based calculations: atropine 0.05 mg/kg IV (minimum 0.1 mg, maximum 5 mg), 2-PAM 25 to 50 mg/kg IV over 15 to 30 minutes.67
Pyridostigmine Pretreatment as Nerve Agent Prophylaxis. Pyridostigmine bromide (PB) tablets at 30 mg every 8 hours were used as prophylaxis for soman exposure during the 1991 Gulf War. The rationale is that reversible carbamylation of a fraction of AChE by pyridostigmine occupies enzyme sites before nerve agent exposure, and when the pyridostigmine effect spontaneously reverses, active enzyme is regenerated, partially compensating for the nerve agent-inhibited fraction. This strategy works only for soman (because soman ages too quickly for 2-PAM to be useful) and only in combination with atropine and 2-PAM administration at time of exposure. Pyridostigmine is not used alone as a nerve agent antidote; it provides a partial pharmacological buffer that extends the therapeutic window for other antidotes. The practical evidence for its efficacy in humans is limited to retrospective analyses, and its use was associated with Gulf War Illness in some studies, though causality remains controversial. It is not indicated for routine civilian OP pesticide poisoning.311
Both: atropine titrated to secretion drying; benzodiazepines for seizures; airway management priority. OP only: 2-PAM indicated; administer as early as possible; continue 24 to 48 hours or until clinical improvement sustained. Carbamate only: 2-PAM not indicated (spontaneous reactivation; potential paradoxical harm); shorter clinical course; recovery within 6 to 24 hours expected. Distinguishing carbamate from OP exposure in the field is not always possible; administer atropine and benzodiazepines universally, and withhold or use clinical judgment on 2-PAM only if carbamate-only exposure is confirmed by history and context.
Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol. 2013;11(3):315-335.
doi:10.2174/1570159X11311030006Munoz-Quezada MT, Lucero BA, Iglesias VP, et al. Chronic exposure to organophosphate (OP) pesticides and neuropsychological functioning in farm workers: a review. Int J Occup Environ Health. 2016;22(1):68-79.
doi:10.1080/10773525.2015.1123848Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet. 2008;371(9612):597-607.
doi:10.1016/S0140-6736(07)61202-1Karalliedde L, Senanayake N. Organophosphorus insecticide poisoning. Br J Anaesth. 1989;63(6):736-750.
doi:10.1093/bja/63.6.736Jokanovic M. Medical treatment of acute poisoning with organophosphorus and carbamate pesticides. Toxicol Lett. 2009;190(2):107-115.
doi:10.1016/j.toxlet.2009.07.025Holstege CP, Kirk M, Sidell FR. Chemical warfare: nerve agent poisoning. Crit Care Clin. 1997;13(4):923-942.
doi:10.1016/S0749-0704(05)70374-2Eddleston M, Eyer P, Worek F, et al. Differences between organophosphorus insecticides in human self-poisoning: a prospective cohort study. Lancet. 2005;366(9495):1452-1459.
doi:10.1016/S0140-6736(05)67598-8Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia. 2001;42(Suppl 3):8-12.
doi:10.1046/j.1528-1157.2001.042suppl.3008.xReigart JR, Roberts JR. Recognition and Management of Pesticide Poisonings. 6th ed. Washington, DC: US Environmental Protection Agency; 2013. EPA 735-R-13-001.
doi:10.1186/s12940-015-0016-1Bradberry SM, Cage SA, Proudfoot AT, Vale JA. Poisoning due to pyrethroids. Toxicol Rev. 2005;24(2):93-106.
doi:10.2165/00139709-200524020-00003Thiermann H, Worek F, Kehe K. Limitations and challenges in treatment of acute chemical warfare agent poisoning. Chem Biol Interact. 2013;206(3):435-443.
doi:10.1016/j.cbi.2013.09.015Worek F, Thiermann H, Wille T. Oximes in organophosphate poisoning: 60 years of hope and despair. Chem Biol Interact. 2016;259(Pt B):93-98.
doi:10.1016/j.cbi.2016.04.032